Summary: Common weight-loss and type 2 diabetes drugs known as GLP-1 receptor agonists (including semaglutide and liraglutide) have robust preclinical evidence showing they reduce the core biological markers of Alzheimer’s disease.
A systematic review of 30 preclinical studies reports consistent reductions in the two hallmark proteins that define Alzheimer’s pathology — amyloid-beta and hyperphosphorylated tau. While clinical trial data in humans are still limited, the accumulated laboratory evidence supports testing GLP-1 receptor agonists as preventive therapies for dementia.
Key Facts
- Protein reduction: Among the reviewed preclinical studies, 22 reported decreases in amyloid-beta plaques and 19 reported reductions in hyperphosphorylated tau tangles.
- Most studied drug: Liraglutide was the most extensively investigated and showed the most consistent reductions in both amyloid and tau across models.
- Preventive promise: Evidence suggests these drugs are likely to be most effective when used early—before significant cognitive decline or established dementia.
- Mechanisms beyond weight loss: Protective effects likely arise from reduced neuroinflammation, improved brain insulin signalling, and modulation of enzymes involved in amyloid production.
Source: Anglia Ruskin University
Overview
Researchers from Anglia Ruskin University published a systematic review in Molecular and Cellular Neuroscience examining the effects of four GLP-1 receptor agonists—liraglutide, semaglutide, exenatide and dulaglutide—on Alzheimer’s disease pathophysiology. The review synthesised results from 30 preclinical studies and two clinical trials, focusing mainly on how these drugs affect amyloid-beta (Aβ) accumulation and tau hyperphosphorylation.
Across animal and cell models, the review found strong and reproducible effects: most studies reported that GLP-1 receptor agonists reduced amyloid‑beta deposition and decreased levels of hyperphosphorylated tau, the altered form of tau that forms toxic tangles inside neurons. Liraglutide, in particular, showed consistent benefit in multiple models. Dulaglutide and semaglutide also produced promising results in the studies available, while exenatide produced mixed outcomes depending on the model and experimental conditions.
Clinical evidence is still developing. Two human trials included in the review had mixed findings: a 26‑week liraglutide trial did not lower amyloid levels or improve cognition but preserved brain glucose metabolism, an important indicator of neuronal health. An 18‑month exenatide study did not show changes in amyloid or tau in cerebrospinal fluid, though it did report reduced amyloid‑beta levels in extracellular vesicles—an emerging early biomarker.
Alzheimer’s disease is the most common cause of dementia in the UK, currently affecting around 900,000 people, with numbers expected to rise substantially in the next decade. Given the limited effectiveness of current treatments, repurposing GLP-1 receptor agonists offers a promising avenue to prevent or delay disease onset if early intervention can be demonstrated to work in clinical populations.
Dr Simon Cork, lead author and Physiology lead at Anglia Ruskin University’s School of Medicine, noted that the review maps multiple biological pathways through which GLP‑1 drugs may act: lowering neuroinflammation, improving insulin signalling in the brain, and modulating enzymes that generate amyloid‑beta. He emphasised that while preclinical evidence is compelling, larger early-stage clinical trials are needed to determine whether these effects translate into meaningful benefits for people at risk of Alzheimer’s.
Key Questions Answered:
A: Timing and trial design matter. Many human studies have been short or enrolled people with established brain pathology. The review suggests GLP‑1 drugs target upstream disease drivers (plaques and tangles), so they may be most effective when given earlier—years before clinical symptoms appear.
A: The phrase reflects the growing evidence that brain insulin resistance contributes to Alzheimer’s. GLP‑1 drugs improve insulin signalling systemically and appear to restore metabolic function in the brain, which could enhance clearance of toxic proteins and support neuronal health.
A: Yes. While these medications have not yet reversed dementia, liraglutide preserved brain glucose metabolism in a clinical study—an indicator that neurons remained metabolically active. Other early biomarkers, such as amyloid‑beta in extracellular vesicles, have also shown changes in small trials.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper cited in this piece was reviewed in full by the editorial team.
- Additional explanatory context was added for clarity.
About this research and reporting
Author: Jamie Forsyth
Source: Anglia Ruskin University
Contact: Jamie Forsyth – Anglia Ruskin University
Image: The image is credited to Neuroscience News
Original Research: Closed access. “The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review” by Eve Corcoran, Michael Kettlety, Urwa Mogul, Jennifer Ndiforngwah Azah, and Simon C. Cork. Molecular and Cellular Neuroscience. DOI: 10.1016/j.mcn.2026.104091
Abstract
The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review
Background
Alzheimer’s disease incidence is rising worldwide, yet effective disease-modifying therapies remain scarce. GLP-1 receptor (GLP-1R) agonists, drugs commonly used to treat type 2 diabetes and for weight management, have shown neuroprotective properties in laboratory models by reducing tau hyperphosphorylation and limiting beta-amyloid (Aβ) plaque formation.
This systematic review assesses the effects of liraglutide, semaglutide, exenatide and dulaglutide on Alzheimer’s biomarkers, with a focus on hyperphosphorylated tau and Aβ.
Methods
The authors conducted a systematic search of major biomedical databases to identify preclinical and clinical studies that investigated the four specified GLP-1 agonists and their impact on Aβ and tau pathology. Both randomized and non-randomized studies were included; studies of other GLP-1 agents were excluded.
Results
Thirty preclinical studies were analysed. Liraglutide was the most commonly studied agent and consistently reduced both Aβ and tau pathologies in animal and cell models. Dulaglutide and semaglutide also produced largely positive results, including reductions in pathological tau phosphorylation and Aβ accumulation in mouse models, and some improvements in cognitive measures. Exenatide findings were mixed across studies.
Two clinical studies were reviewed: a phase II exenatide trial that reduced plasma Aβ42 in extracellular vesicles but did not improve cognition, and a liraglutide trial that preserved brain glucose metabolism without clear reductions in Aβ burden or cognitive change. Additional trials have reported changes in systemic inflammatory markers, but overall clinical evidence remains limited compared with preclinical data.
Conclusions
Preclinical data provide consistent support that GLP-1 receptor agonists reduce Aβ levels and hyperphosphorylated tau, indicating neuroprotective potential. To confirm clinical benefit, larger, well-designed early-stage human trials are needed, particularly those that target people at high risk before significant cognitive decline.
Registration
PROSPERO CRD420251029748.